Regenerative Medicines for Alzheimer’s Disease | A Pipeline Analysis Report 2018 | Technavio

Technavio has published a new report on the drug development pipeline for regenerative medicines for Alzheimer’s disease, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the regenerative medicines for Alzheimer’s disease market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period for regenerative medicines for Alzheimer’s disease.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Regenerative medicines for Alzheimer’s disease: Market overview

Alzheimer’s disease is a chronic neurodegenerative disorder that worsens over time. It is the most common type of neurodegenerative disorder. It is responsible for 60%-80% of dementias. It affects the cognitive functions to the extent that the patients find it difficult to perform day-to-day tasks. It results in a progressive decline in cognition. One of the major causes of the disease is old age. However, studies have shown that people aged under 65 years could also develop Alzheimer’s disease.

According to a senior analyst at Technavio for research on infectious and rare diseases, “One of the known causes of Alzheimer’s disease is the overexpression of the tau protein, this leads to its accumulation in the neurons, causing neurofibrillary tangles. The tau accumulation interferes with the signaling pathway of the neurons, which causes difficulty with the cognitive functions.”

Regenerative medicines for Alzheimer’s disease: Segmentation analysis

This market research report segments the regenerative medicines for Alzheimer’s disease market based on therapies employed that includes monotherapy, RoA (intravenous, intracerebral, and unknown), therapeutic modalities (gene and stem cell), targets for drugs under development (Tau protein, VLDLR and ApoER2, CYP46A1, Klotho, hTERT, β-amyloid, and endosome), MoA (gene therapy and cell replacements), drugs under development (discovery, pre-clinical, phase I, phase I/II, and phase II), and recruitment status (not yet recruiting, recruiting, active not recruiting, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company Overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline on regenerative medicines for Alzheimer’s disease.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com